EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease

Mingxi Dang, Qian Chen, Xiaobin Zhao, Kewei Chen, Xin Li, Junying Zhang, Jie Lu iD, Lin Ai, Yaojing Chen, Zhanjun Zhang iD

Human Brain Mapping · 2023-02 · 44 (2) · 327-340

DOI: 10.1002/hbm.26043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Brain Mapping, online erschienen am 14.08.2022. Verfasst von Mingxi Dang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The A/T/N research framework has been proposed for the diagnosis and prognosis of Alzheimer's disease (AD). However, the spatial distribution of ATN biomarkers and their relationship with cognitive impairment and neuropsychiatric symptoms (NPS) need further clarification in patients with AD. We scanned 83 AD patients and 38 cognitively normal controls who independently completed the mini‐mental state examination and Neuropsychiatric Inventory scales. Tau, Aβ, and hypometabolism spatial patterns were characterized using Statistical Parametric Mapping together with [18F]flortaucipir, [18F]florbetapir, and [18F]FDG positron emission tomography. Piecewise linear regression, two‐sample t ‐tests, and support vector machine algorithms were used to explore the relationship between tau, Aβ, and hypometabolism and cognition, NPS, and AD diagnosis. The results showed that regions with tau deposition are region‐specific and mainly occurred in inferior temporal lobes in AD, which extensively overlaps with the hypometabolic regions. While the deposition regions of Aβ were unique and the regions affected by hypometabolism were widely distributed. Unlike Aβ, tau and hypometabolism build up monotonically with increasing cognitive impairment in the late stages of AD. In addition, NPS in AD were associated with tau deposition closely, followed by hypometabolism, but not with Aβ. Finally, hypometabolism and tau had higher accuracy in differentiating the AD patients from controls (accuracy = 0.88, accuracy = 0.85) than Aβ (accuracy = 0.81), and the combined three were the highest (accuracy = 0.95). These findings suggest tau pathology is superior over Aβ and glucose metabolism to identify cognitive impairment and NPS. Its results support tau accumulation can be used as a biomarker of clinical impairment in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansBrainPositron-Emission TomographyBiomarkerstau ProteinsAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid-βcognitive impairmenthypometabolismneuropsychiatric symptomstau

Substanzen

Biomarkerstau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China.
  • BABRI Centre, Beijing Normal University, Beijing, China.
  • Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.
  • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
  • Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China.

ORCID-Profile: Jie Lu, Zhanjun Zhang

Förderung

  • NIA NIH HHS
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • National Science Fund for Distinguished Young Scholars

Zitieren

APA

Dang, M., Chen, Q., Zhao, X., Chen, K., Li, X., Zhang, J., Lu, J., Ai, L., Chen, Y., & Zhang, Z. (2023). Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease. Human Brain Mapping, 44(2), 327-340. https://doi.org/10.1002/hbm.26043

Vancouver

Dang M, Chen Q, Zhao X, Chen K, Li X, Zhang J, et al. Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease. Human Brain Mapping. 2023;44(2):327-340. doi:10.1002/hbm.26043

BibTeX
@article{Dang2023,
  author = {Dang, Mingxi and Chen, Qian and Zhao, Xiaobin and Chen, Kewei and Li, Xin and Zhang, Junying and Lu, Jie and Ai, Lin and Chen, Yaojing and Zhang, Zhanjun},
  title = {Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease},
  journal = {Human Brain Mapping},
  year = {2023},
  volume = {44},
  number = {2},
  pages = {327--340},
  doi = {10.1002/hbm.26043}
}
Kostenlos starten →